Your browser is no longer supported. Please, upgrade your browser.
NTRP Neurotrope, Inc. daily Stock Chart
Neurotrope, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own17.87% Shs Outstand23.67M Perf Week5.36%
Market Cap28.15M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float19.79M Perf Month-1.67%
Income-13.00M PEG- EPS next Q- Inst Own9.50% Short Float0.42% Perf Quarter-9.92%
Sales- P/S- EPS this Y14.90% Inst Trans-3.41% Short Ratio0.22 Perf Half Y3.51%
Book/sh1.77 P/B0.67 EPS next Y- ROA-56.20% Target Price- Perf Year-79.48%
Cash/sh1.35 P/C0.87 EPS next 5Y- ROE-57.70% 52W Range0.63 - 6.59 Perf YTD20.14%
Dividend- P/FCF- EPS past 5Y40.60% ROI- 52W High-82.11% Beta2.19
Dividend %- Quick Ratio93.50 Sales past 5Y- Gross Margin- 52W Low87.30% ATR0.07
Employees5 Current Ratio93.50 Sales Q/Q- Oper. Margin- RSI (14)46.21 Volatility8.09% 5.57%
OptionableYes Debt/Eq0.00 EPS Q/Q61.60% Profit Margin- Rel Volume0.65 Prev Close1.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume387.55K Price1.18
Recom3.00 SMA200.90% SMA50-5.30% SMA2009.22% Volume99,644 Change0.00%
Sep-11-19Downgrade Janney Buy → Neutral $1
Jun-18-19Initiated Janney Buy $14
May-16-18Initiated Maxim Group Buy $16
Jun-24-20 05:21AM  
Jun-12-20 01:00PM  
Jun-10-20 08:41AM  
May-28-20 09:00AM  
May-26-20 04:20PM  
May-20-20 07:15PM  
May-18-20 08:45AM  
Mar-18-20 10:13AM  
Feb-03-20 05:15PM  
Jan-24-20 12:04PM  
Jan-22-20 02:05PM  
Dec-19-19 01:41PM  
Oct-08-19 08:30AM  
Oct-04-19 10:09AM  
Oct-01-19 09:14AM  
Sep-30-19 09:58AM  
Sep-27-19 08:45AM  
Sep-26-19 11:24AM  
Sep-24-19 11:25AM  
Sep-23-19 09:44AM  
Sep-20-19 11:44AM  
Sep-19-19 08:41AM  
Sep-18-19 09:22AM  
Sep-16-19 08:29AM  
Sep-13-19 10:54AM  
Sep-11-19 09:04AM  
Sep-10-19 08:00AM  
Sep-09-19 03:05PM  
Sep-05-19 08:19AM  
Aug-21-19 10:41AM  
Aug-13-19 08:30AM  
Aug-05-19 08:30AM  
Jul-17-19 08:30AM  
Jul-15-19 08:30AM  
Jul-11-19 08:30AM  
Jun-24-19 08:30AM  
Jun-03-19 08:30AM  
May-30-19 08:30AM  
May-27-19 08:11AM  
Apr-19-19 05:15PM  
Apr-01-19 08:30AM  
Mar-21-19 09:55AM  
Mar-13-19 08:30AM  
Mar-11-19 08:30AM  
Feb-08-19 08:30AM  
Feb-04-19 08:30AM  
Jan-03-19 08:30AM  
Dec-24-18 10:46AM  
Dec-17-18 09:02AM  
Nov-19-18 09:00AM  
Oct-24-18 08:30AM  
Sep-27-18 08:30AM  
Sep-26-18 08:30AM  
Sep-05-18 08:30AM  
Aug-30-18 06:45AM  
Aug-28-18 08:30AM  
Aug-13-18 08:30AM  
Jul-25-18 08:30AM  
Jul-17-18 02:17PM  
Jul-16-18 08:30AM  
Jul-11-18 08:30AM  
Jul-02-18 08:30AM  
May-07-18 08:30AM  
Mar-09-18 10:21AM  
Feb-28-18 08:30AM  
Feb-07-18 08:30AM  
Jan-25-18 08:30AM  
Jan-05-18 09:28AM  
Dec-19-17 08:30AM  
Dec-18-17 08:30AM  
Aug-09-17 08:30AM  
Jul-19-17 11:16AM  
Jul-17-17 11:36AM  
Jul-14-17 11:58PM  
May-03-17 02:58PM  
May-01-17 04:17PM  
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.